Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05281406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 21, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Nov 2023 to Nov 2025 Study sites: 14 to 16v4 Show 1 more changeShow less
    • Study sites: 14 to 16
  2. Study sites: 9 to 14v3
  3. Study sites: 1 to 9v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.
Trial Details
NCT Number NCT05281406
Lead Sponsor Goethe University
Conditions NSCLC Stage IIIB, NSCLC Stage IV
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov